A Phase 3 interventional study of Inclisiran in Atherosclerotic Cardiovascular Disease, sponsored by Novartis Pharmaceuticals. Completed at 43 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-16.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing inclisiran in Atherosclerosis — 3 open to participants now, 7 under way, 4 of them phase 3. inclisiran · Atherosclerosis.
Among the 16 studies testing inclisiran in Atherosclerosis, this one is the 7th largest by enrollment, is one of 4 that started in 2021, is one of 8 in phase 3, and was the 7th registered.
1,519 studies on the registry are indexed under Atherosclerosis; 226 are open to participants now.
Browse Atherosclerosis studies →3 of the 16 studies testing inclisiran in Atherosclerosis are open now, in 4 countries. Recruiting first, the newest first:
University Medical Centre Ljubljana · Sites in Slovenia
Ages 18+
Novartis Pharmaceuticals · Sites in Argentina, Brazil
Ages 18–100
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 30–50
By country, each count listing its studies:
inclisiran: first FDA approval 2021 (LEQVIO), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 163 Atherosclerosis studies recruiting now, 85 (52%) set no upper age limit and 34 (21%) stop at 75 or younger; 16 take children under 18; 35 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 4 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 450 is above the median of 100 across 881 interventional studies indexed under Atherosclerosis.
Median enrollment 401 across the 16 interventional studies. Of the 8 that completed or were terminated, 6 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 16 have an industry lead sponsor. The 8 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
27 studies in Atherosclerosis by Novartis: 4 open now, 10 under way, 3 of them phase 3. Of 16 finished, 10 (63%) have results posted.
Among the 27 studies in Atherosclerosis by Novartis, this one is the 9th largest by enrollment of the 18 interventional ones that give a count, is one of 4 that started in 2021, is one of 10 in phase 3, and was the 10th registered.
Novartis’s Atherosclerosis studies by the year they started, since 2006.
4 of the studies testing inclisiran in Atherosclerosis that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05030428Phase 3Novartis PharmaceuticalsStudy of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease | 2027-05-10 |
| NCT06501443Novartis PharmaceuticalsLATAM LOWERS LDL-C | 2026-11-27 |
| NCT06249165Duke UniversityVictORION-INCLUSION: Evaluating Inclisiran for Cholesterol Managment in Heart Disease | 2026-12-31 |
| NCT07581808University Medical Centre LjubljanaDual PCSK9 Inhibition With Inclisiran and Alirocumab in Secondary Prevention | 2027-05 |
Add all 4 to your calendar (.ics) → With an account.
Among the 16 studies testing inclisiran in Atherosclerosis, from their registry updates:
Among Novartis’s 27 in Atherosclerosis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to assess the effectiveness of an "inclisiran first" implementation strategy (addition of inclisiran to maximally tolerated statin therapy immediately upon failure to achieve acceptable LDL-C with maximally tolerated statin therapy alone) compared to usual care in an atherosclerotic cardiovascular disease (ASCVD) population.
The study design was a randomized, two-arm, parallel-group, open-label, multicenter, clinical trial comparing an "inclisiran first" implementation strategy to usual care (1:1 randomization) with established ASCVD and elevated LDL-C (or non-HDL-C) despite treatment with maximally tolerated statin therapy.
Eligible patients had established ASCVD and elevated LDL-C levels ≥ 70 mg/dL (or non-HDL-C ≥ 100 mg/dL) despite treatment with maximally tolerated statin therapy.
In the "inclisiran first" implementation strategy group post-randomization, addition of other non-statin LDL-C lowering therapies (e.g., ezetimibe or bempedoic acid, excluding PCSK9 inhibiting monoclonal antibodies) were allowed to reach acceptable LDL-C levels. In the "inclisiran first" implementation strategy group, inclisiran was administered initially at randomization, 90 days later, and six months, thereafter.
Participants eligible for inclusion in this study must meet all of the following criteria:
History of ASCVD, documented by hospital records, claims data and/or prior laboratory/imaging assessments a Coronary heart disease (CHD):
Exclusion Criteria:
Participants meeting any of the following criteria are not eligible for inclusion in this study.
Women of , defined as all women physiologically capable of becoming pregnant, unless they are using basic methods of during dosing of drug. Basic contraception methods include:
Women are considered and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy or tubal ligation at least six weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of child bearing potential.
Any condition that according to the investigator could interfere with the conduct of the study, such as but not limited to:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Inclisiran sodium 300 mg 1.5 ml (equivalent to 284 mg of inclisiran) + usual care
Drug: Inclisiran
Treating physicians were recommended to treat patients in accordance with the 2018 ACC/AHA guidelines
Inclisiran sodium 300 mg/1.5 ml (equivalent to 284 mg inclisiran liquid) in prefilled syringe (PFS).
Also known as: Inclisiran First
Percent Change From Baseline in LDL-C
Percent change from baseline in Low-Density Lipoprotein Cholesterol (LDL-C) of an "inclisiran first" implementation strategy compared to usual care at Day 330.
Time frame: Baseline, Day 330
Percentage of Participants Who Discontinued Statin Therapy
Percentage of patients who discontinued statin therapy ≥ 30 days before the end-of-study visit of an "inclisiran first" implementation strategy compared to usual care, for patients in the FAS excluding those with a medical history of statin intolerance.
Time frame: Day 330
Absolute Change From Baseline in LDL-C
Absolute change in Low-Density Lipoprotein Cholesterol (LDL-C) of an "inclisiran first" implementation strategy compared to usual care at Day 330
Time frame: Baseline, Day 330
Average Percent Change From Baseline in LDL-C Levels Across Visits
Average percent change in Low-Density Lipoprotein Cholesterol (LDL-C) of an "inclisiran first" implementation strategy compared to usual care across visits. Calculated by averaging the observed post-baseline values (percent change) for each participant across analysis visits.
Time frame: Up to 330 Days
Average Absolute Change From Baseline in LDL-C Levels Across Visits
Average absolute change in Low-Density Lipoprotein Cholesterol (LDL-C) of an "inclisiran first" implementation strategy compared to usual care across visits. Calculated by averaging the observed post-baseline values (absolute change) for each participant across analysis visits.
Time frame: Up to 330 days
Percentage of Participants Achieving ≥ 50% Reduction From Baseline in LDL-C
Percentage of patients achieving a ≥ 50% reduction from baseline in Low-Density Lipoprotein Cholesterol (LDL-C) levels of an "inclisiran first" implementation strategy compared to usual care at Day 330. Missing data is imputed using "non-responder" (i.e., "negative" outcome) imputation.
Time frame: Baseline, Day 330
Percentage of Participants Achieving LDL-C < 100 mg/dL.
Percentage of participants achieving Low-Density Lipoprotein Cholesterol (LDL-C) \< 100 mg/dL (among the subset of participants with LDL-C \>=100 mg/dL at baseline) of an "inclisiran first" implementation strategy compared to usual care at Day 330. Missing data is imputed using "non-responder" (i.e., "negative" outcome) imputation.
Time frame: Day 330
Percentage of Participants Achieving LDL-C < 70 mg/dL
Percentage of participants achieving Low-Density Lipoprotein Cholesterol (LDL-C) \< 70 mg/dL of an "inclisiran first" implementation strategy compared to usual care at Day 330. Missing data is imputed using "non-responder" (i.e., "negative" outcome) imputation.
Time frame: Day 330
Percentage of Participants Achieving LDL-C < 55 mg/dL
Percentage of participants achieving Low-Density Lipoprotein Cholesterol (LDL-C) \< 55 mg/dL of an "inclisiran first" implementation strategy compared to usual care at Day 330. Missing data is imputed using "non-responder" (i.e., "negative" outcome) imputation.
Time frame: Day 330
Percent Change in Lipids and Other Lipoproteins From Baseline
Percent change in plasma lipids, lipoproteins and triglycerides in participants receiving an "inclisiran first" implementation strategy compared to usual care at Day 330
Time frame: Baseline, Day 330
Absolute Change in Lipids and Other Lipoproteins From Baseline
Absolute change in plasma lipids, lipoproteins and triglycerides in participants receiving an "inclisiran first" implementation strategy compared to usual care at Day 330
Time frame: Baseline, Day 330
Percentage of Participants by Intensity of Lipid Lowering Therapy
Percentage of participants with decrease in dose, no change in dose or increase in dose to assess changes in background lipid-lowering therapy in participants receiving an "inclisiran first" implementation strategy compared to usual care at Day 330
Time frame: Baseline, Day 330
Proportion of Days Covered by Medication
Proportion of days covered refers to the total number of days on either statin, ezetimibe, bempedoic acid or PCSK9 inhibiting monoclonal antibody therapies taken during the study divided by total number of study days, calculated for each participant; If a participant did not take any of the four medications then the total number of days will be assumed to be zero.
Time frame: Up to 330 Days
LDL-C Measures of Variability - Standard Deviation
Visit-to-visit LDL-C variability from Day 90 until Day 330 of an "inclisiran first" implementation strategy compared to usual care. It was assessed using two measures of variability: standard deviation and coefficient of variation.
Time frame: Day 90, Day 180, Day 270 and Day 330
LDL-C Measures of Variability - Coefficient of Variation
Visit-to-visit LDL-C variability from Day 90 until Day 330 of an "inclisiran first" implementation strategy compared to usual care. It was assessed using two measures of variability: standard deviation and coefficient of variation.
Time frame: Day 90, Day 180, Day 270 and Day 330
The study was conducted in 43 centers in the United States
| Milestone | Inclisiran First | Usual Care |
|---|---|---|
| Started | 225 | 225 |
| Full analysis set (fas) | 225 | 225 |
| Safety set | 234 | 216 |
| Completed | 212 | 195 |
| Not completed | 13 | 30 |
| Withdrew: Adverse event | 2 | 1 |
| Withdrew: Death | 2 | 1 |
| Withdrew: Lost to follow-up | 3 | 11 |
| Withdrew: Technical problems | 0 | 1 |
| Withdrew: Subject decision | 6 | 8 |
| Withdrew: Withdrew consent | 0 | 8 |
Percent change from baseline in Low-Density Lipoprotein Cholesterol (LDL-C) of an "inclisiran first" implementation strategy compared to usual care at Day 330.
| percent change in LDL-C | Inclisiran First | Usual Care |
|---|---|---|
| Percent Change From Baseline in LDL-C | -60.0 (-64.7 to -55.2) | -7.0 (-12.0 to -1.9) |
Percentage of patients who discontinued statin therapy ≥ 30 days before the end-of-study visit of an "inclisiran first" implementation strategy compared to usual care, for patients in the FAS excluding those with a medical history of statin intolerance.
| Percentage of participants | Inclisiran First | Usual Care |
|---|---|---|
| Percentage of Participants Who Discontinued Statin Therapy | 6.0 (1.9 to 10.2) | 16.7 (10.2 to 23.1) |
Absolute change in Low-Density Lipoprotein Cholesterol (LDL-C) of an "inclisiran first" implementation strategy compared to usual care at Day 330
| mg/dL | Inclisiran First | Usual Care |
|---|---|---|
| Absolute Change From Baseline in LDL-C | -58.0 (-61.6 to -54.4) | -10.5 (-14.3 to -6.6) |
Average percent change in Low-Density Lipoprotein Cholesterol (LDL-C) of an "inclisiran first" implementation strategy compared to usual care across visits. Calculated by averaging the observed post-baseline values (percent change) for each participant across analysis visits.
| Average percent change in LDL-C | Inclisiran First | Usual Care |
|---|---|---|
| Average Percent Change From Baseline in LDL-C Levels Across Visits | -57.2 (-60.3 to -54.0) | -2.8 (-6.0 to 0.5) |
Average absolute change in Low-Density Lipoprotein Cholesterol (LDL-C) of an "inclisiran first" implementation strategy compared to usual care across visits. Calculated by averaging the observed post-baseline values (absolute change) for each participant across analysis visits.
| mg/dL | Inclisiran First | Usual Care |
|---|---|---|
| Average Absolute Change From Baseline in LDL-C Levels Across Visits | -55.0 (-57.8 to -52.2) | -6.0 (-8.9 to -3.2) |
Percentage of patients achieving a ≥ 50% reduction from baseline in Low-Density Lipoprotein Cholesterol (LDL-C) levels of an "inclisiran first" implementation strategy compared to usual care at Day 330. Missing data is imputed using "non-responder" (i.e., "negative" outcome) imputation.
| Percentage of participants | Inclisiran First | Usual Care |
|---|---|---|
| Percentage of Participants Achieving ≥ 50% Reduction From Baseline in LDL-C | 69.8 | 5.3 |
Percentage of participants achieving Low-Density Lipoprotein Cholesterol (LDL-C) \< 100 mg/dL (among the subset of participants with LDL-C \>=100 mg/dL at baseline) of an "inclisiran first" implementation strategy compared to usual care at Day 330. Missing data is imputed using "non-responder" (i.e., "negative" outcome) imputation.
| Percentage of participants | Inclisiran First | Usual Care |
|---|---|---|
| Percentage of Participants Achieving LDL-C < 100 mg/dL. | 80.5 | 32.1 |
Percentage of participants achieving Low-Density Lipoprotein Cholesterol (LDL-C) \< 70 mg/dL of an "inclisiran first" implementation strategy compared to usual care at Day 330. Missing data is imputed using "non-responder" (i.e., "negative" outcome) imputation.
| Percentage of participants | Inclisiran First | Usual Care |
|---|---|---|
| Percentage of Participants Achieving LDL-C < 70 mg/dL | 81.8 | 22.2 |
Percentage of participants achieving Low-Density Lipoprotein Cholesterol (LDL-C) \< 55 mg/dL of an "inclisiran first" implementation strategy compared to usual care at Day 330. Missing data is imputed using "non-responder" (i.e., "negative" outcome) imputation.
| Percentage of participants | Inclisiran First | Usual Care |
|---|---|---|
| Percentage of Participants Achieving LDL-C < 55 mg/dL | 71.6 | 8.9 |
Percent change in plasma lipids, lipoproteins and triglycerides in participants receiving an "inclisiran first" implementation strategy compared to usual care at Day 330
| Percent change | Inclisiran First | Usual Care |
|---|---|---|
| Total Cholesterol | -34.1 (-36.7 to -31.6) | -4.1 (-6.8 to -1.4) |
| HDL Cholesterol | 8.5 (6.5 to 10.6) | 2.0 (-0.2 to 4.2) |
| Non-HDL Cholesterol | -49.3 (-52.7 to -46.0) | -5.1 (-8.7 to -1.6) |
| VLDL Cholesterol | -10.1 (-14.8 to -5.4) | 6.8 (1.8 to 11.9) |
| Triglycerides | -10.6 (-15.3 to -5.9) | 7.2 (2.1 to 12.2) |
| Apolipoprotein B | -46.4 (-49.7 to -43.1) | -3.8 (-7.3 to -0.3) |
| Lipoprotein(a) | -19.6 (-22.2 to -16.9) | 2.3 (-0.5 to 5.2) |
Absolute change in plasma lipids, lipoproteins and triglycerides in participants receiving an "inclisiran first" implementation strategy compared to usual care at Day 330
| mg/dL | Inclisiran First | Usual Care |
|---|---|---|
| Total Cholesterol | -59.6 (-63.8 to -55.5) | -9.7 (-14.1 to -5.2) |
| HDL Cholesterol | 3.5 (2.6 to 4.4) | 0.3 (-0.6 to 1.3) |
| Non-HDL Cholesterol | -63.0 (-66.9 to -59.1) | -10.5 (-14.7 to -6.4) |
| VLDL Cholesterol | -4.6 (-5.9 to -3.4) | 0.0 (-1.4 to 1.3) |
| Triglycerides | -25.4 (-31.9 to -18.9) | -0.1 (-7.0 to 6.8) |
| Apolipoprotein B | -43.6 (-45.9 to -41.3) | -7.3 (-9.8 to -4.8) |
| Lipoprotein(a) | -9.8 (-11.1 to -8.4) | -1.0 (-2.5 to 0.4) |
Percentage of participants with decrease in dose, no change in dose or increase in dose to assess changes in background lipid-lowering therapy in participants receiving an "inclisiran first" implementation strategy compared to usual care at Day 330
| Percentage of participants | Inclisiran First | Usual Care |
|---|---|---|
| Decrease in statin intensity | 2.3 | 4.5 |
| No change in statin intensity | 97.2 | 93.0 |
| Increase in statin intensity | 0.5 | 2.5 |
Proportion of days covered refers to the total number of days on either statin, ezetimibe, bempedoic acid or PCSK9 inhibiting monoclonal antibody therapies taken during the study divided by total number of study days, calculated for each participant; If a participant did not take any of the four medications then the total number of days will be assumed to be zero.
| proportion of days covered | Inclisiran First | Usual Care |
|---|---|---|
| Proportion of Days Covered by Medication | 0.894 ± 0.0169 | 0.902 ± 0.0169 |
Visit-to-visit LDL-C variability from Day 90 until Day 330 of an "inclisiran first" implementation strategy compared to usual care. It was assessed using two measures of variability: standard deviation and coefficient of variation.
| mg/dL | Inclisiran First | Usual Care |
|---|---|---|
| Day 90 | 42.6 ± 27.21 | 94.3 ± 38.33 |
| Day 180 | 41.1 ± 28.39 | 91.2 ± 31.61 |
| Day 270 | 46.2 ± 31.22 | 88.4 ± 32.16 |
| Day 330 | 38.8 ± 25.33 | 86.8 ± 35.47 |
Visit-to-visit LDL-C variability from Day 90 until Day 330 of an "inclisiran first" implementation strategy compared to usual care. It was assessed using two measures of variability: standard deviation and coefficient of variation.
| Coefficient of Variation | Inclisiran First | Usual Care |
|---|---|---|
| Day 90 | 63.90 | 40.65 |
| Day 180 | 69.00 | 34.67 |
| Day 270 | 67.56 | 36.38 |
| Day 330 | 65.34 | 40.89 |
Collected over Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 330 days or until resolution.. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Inclisiran First | 2/234 (0.9%) | 27/234 (11.5%) | 64/234 (27.4%) |
| Usual Care | 1/216 (0.5%) | 29/216 (13.4%) | 53/216 (24.5%) |
| Event | Inclisiran First | Usual Care |
|---|---|---|
| Acute myocardial infarctionCardiac disorders | 4/234 | 2/216 |
| Non-cardiac chest painGeneral disorders | 1/234 | 3/216 |
| Carotid artery stenosisNervous system disorders | 0/234 | 3/216 |
| PneumoniaInfections and infestations | 3/234 | 2/216 |
| SepsisInfections and infestations | 3/234 | 1/216 |
| FallInjury, poisoning and procedural complications | 3/234 | 1/216 |
| Coronary artery diseaseCardiac disorders | 1/234 | 2/216 |
| Urinary tract infectionInfections and infestations | 1/234 | 2/216 |
| Cerebrovascular accidentNervous system disorders | 1/234 | 2/216 |
| Transient ischaemic attackNervous system disorders | 1/234 | 2/216 |
| Event | Inclisiran First | Usual Care |
|---|---|---|
| Injection site painGeneral disorders | 18/234 | 0/216 |
| COVID-19Infections and infestations | 18/234 | 14/216 |
| Blood creatine phosphokinase increasedInvestigations | 10/234 | 13/216 |
| Type 2 diabetes mellitusMetabolism and nutrition disorders | 8/234 | 10/216 |
| FallInjury, poisoning and procedural complications | 3/234 | 9/216 |
| Glycosylated haemoglobin increasedInvestigations | 9/234 | 5/216 |
| Urinary tract infectionInfections and infestations | 8/234 | 7/216 |
| Age, Continuous(years) | Inclisiran First | Usual Care | Total |
|---|---|---|---|
| Mean | 66.3 ± 9.01 | 66.8 ± 9.84 | 66.5 ± 9.43 |
| Sex: Female, Male(Participants) | Inclisiran First | Usual Care | Total |
|---|---|---|---|
| Female | 67 | 72 | 139 |
| Male | 158 | 153 | 311 |
| Race/Ethnicity, Customized(Participants) | Inclisiran First | Usual Care | Total |
|---|---|---|---|
| White | 186 | 187 | 373 |
| Black or African American | 27 | 29 | 56 |
| Asian | 8 | 4 | 12 |
| Unknown | 4 | 4 | 8 |
| Multiple | 0 | 1 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Jun 2021 to primary completion in Sep 2023, 26 months.
Results were first posted in Sep 2024, 1 year after primary completion.
Of 36 industry-sponsored phase 3 interventional studies under Atherosclerosis, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 51. This study's 26 months is below that.
Counting every sponsor, half of 53 studies reached it within 35 months; a quarter within 21 and three quarters within 63.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Inclisiran